ES2156866T3 - Derivados de 1-bifenilmetilimidazol, su preparacion y su uso terapeutico. - Google Patents

Derivados de 1-bifenilmetilimidazol, su preparacion y su uso terapeutico.

Info

Publication number
ES2156866T3
ES2156866T3 ES93200195T ES93200195T ES2156866T3 ES 2156866 T3 ES2156866 T3 ES 2156866T3 ES 93200195 T ES93200195 T ES 93200195T ES 93200195 T ES93200195 T ES 93200195T ES 2156866 T3 ES2156866 T3 ES 2156866T3
Authority
ES
Spain
Prior art keywords
rent
hydrogen
formula
carboxi
arilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93200195T
Other languages
English (en)
Spanish (es)
Inventor
Hiroaki Yanagisawa
Yasuo Shimoji
Koichi Fujimoto
Takuro Kanazaki
Yoshiya Amemiya
Hiroyuki Koike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2156866(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2156866T3 publication Critical patent/ES2156866T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES93200195T 1991-02-21 1992-02-21 Derivados de 1-bifenilmetilimidazol, su preparacion y su uso terapeutico. Expired - Lifetime ES2156866T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP9658891 1991-04-26
JP13488991 1991-06-06
JP16713891 1991-07-08
JP17397291 1991-07-15
JP18484191 1991-07-24

Publications (1)

Publication Number Publication Date
ES2156866T3 true ES2156866T3 (es) 2001-08-01

Family

ID=27549327

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93200195T Expired - Lifetime ES2156866T3 (es) 1991-02-21 1992-02-21 Derivados de 1-bifenilmetilimidazol, su preparacion y su uso terapeutico.
ES92301449T Active ES2157895T7 (es) 1991-02-21 1992-02-21 Derivados de 1-bifenilimidazo, su preparacion y su uso terapéutico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES92301449T Active ES2157895T7 (es) 1991-02-21 1992-02-21 Derivados de 1-bifenilimidazo, su preparacion y su uso terapéutico.

Country Status (22)

Country Link
EP (2) EP0503785B3 (cs)
JP (1) JPH07121918B2 (cs)
KR (1) KR0128289B1 (cs)
CN (3) CN1045770C (cs)
AT (2) ATE200777T1 (cs)
CA (2) CA2061607C (cs)
CZ (1) CZ289194B6 (cs)
DE (6) DE122009000024I1 (cs)
DK (2) DK0545912T3 (cs)
ES (2) ES2156866T3 (cs)
FI (2) FI112942B3 (cs)
GR (2) GR3035909T3 (cs)
HU (3) HU223338B1 (cs)
IE (1) IE920540A1 (cs)
IL (3) IL114996A (cs)
IS (1) IS1756B (cs)
LU (4) LU91056I2 (cs)
NL (3) NL300133I2 (cs)
NO (6) NO304516B3 (cs)
NZ (1) NZ241681A (cs)
PT (2) PT545912E (cs)
RU (1) RU2128173C1 (cs)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
DK0573218T3 (da) * 1992-06-02 2001-06-18 Sankyo Co 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse
CZ283315B6 (cs) * 1992-12-17 1998-02-18 Sankyo Company Limited Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
ATE266402T1 (de) * 1994-03-16 2004-05-15 Sankyo Co Okulares hypotonikum
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
DE69731840T2 (de) 1996-07-15 2005-08-04 Sankyo Co., Ltd. Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom
WO1998034922A1 (fr) * 1997-02-05 1998-08-13 Sankyo Company, Limited Agent destine a la prophylaxie ou la therapie des complications diabetiques
USD441509S1 (en) 1997-08-25 2001-05-01 Mastrad S.A. Combined hand cleaner and hand cleaner base
AU141230S (en) 1999-02-26 2000-07-25 Unilever Plc Detergent tablet
CA2375287A1 (en) * 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Production method of imidazole derivatives
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002214324B2 (en) * 2000-11-21 2004-07-29 Daiichi Sankyo Company, Limited Medicinal compositions
MXPA04001878A (es) * 2001-08-28 2004-06-15 Sankyo Co Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
MXPA05008142A (es) 2003-01-31 2005-09-30 Sankyo Co Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension.
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
BRPI0409293A (pt) * 2003-04-15 2006-04-11 Sankyo Co medicamento para a prevenção ou tratamento de doenças angiogênicas intraoculares
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
RU2426532C2 (ru) 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
CN1976926A (zh) * 2004-09-02 2007-06-06 特瓦制药工业有限公司 奥美沙坦酯的制备
ES2384637T3 (es) 2004-10-08 2012-07-10 Novartis Ag Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
CA2585623C (en) 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Ortho-substituted benzene derivatives
EP1716138A1 (en) * 2004-12-30 2006-11-02 Teva Pharmaceutical Industries Ltd Process for preparing olmesartan medoxomil at ph higher than 2.5
CN101094850A (zh) * 2005-01-03 2007-12-26 特瓦制药工业有限公司 具有较低水平杂质的奥美沙坦酯
JP5051897B2 (ja) * 2005-04-22 2012-10-17 第一三共株式会社 骨代謝性疾患の予防又は治療のための医薬
EP1816131A1 (en) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of olmesartan medoxomil
EP1910343B1 (en) * 2005-07-29 2014-10-29 Krka Process for the preparation of olmesartan medoxomil
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (en) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Novel polymorph forms of olmesartan medoxomil
EP1990052B1 (en) * 2006-02-27 2012-05-16 Takeda Pharmaceutical Company Limited Pharmaceutical package comprising 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl and a desiccant.
SI1891952T1 (sl) 2006-05-04 2012-02-29 Lek Pharmaceuticals, D.D. Farmacevtski sestavek, ki vsebuje olmesartan medoksomil
WO2007148344A2 (en) * 2006-06-19 2007-12-27 Matrix Laboratories Limited Process for the preparation of olmesartan medoxomil
CA2677661A1 (en) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
CA2681591A1 (en) * 2007-03-23 2008-10-02 Daiichi Sankyo Company, Limited Pulverized crystals of olmesartan medoxomil
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
JP5311413B2 (ja) * 2007-06-22 2013-10-09 第一三共株式会社 アルツハイマー病の予防又は治療のための医薬
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009151016A1 (ja) * 2008-06-09 2009-12-17 第一三共株式会社 １－ビフェニルメチルイミダゾール化合物の製造方法
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2327690A4 (en) 2008-08-06 2012-03-28 Kyowa Hakko Kirin Co Ltd TRICYCLIC CONNECTION
US8618308B2 (en) 2008-11-17 2013-12-31 Shanghai Institute Of Pharmaceutical Industry Process for the preparation of 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylates
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CA2759163C (en) 2009-04-28 2015-02-17 Daiichi Sankyo Company, Limited Method for producing olmesartan medoxomil
MY158090A (en) 2009-04-28 2016-08-30 Daiichi Sankyo Co Ltd Novel solvate crystals
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
WO2011083112A2 (en) 2010-01-05 2011-07-14 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN103874697A (zh) 2011-08-03 2014-06-18 协和发酵麒麟株式会社 二苯并氧杂*衍生物
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
EP2891650B1 (en) 2012-08-31 2018-08-01 API Corporation Method for producing biaryl compound
EP2902385B1 (en) 2012-09-26 2019-01-09 API Corporation Deprotection method for tetrazole compound
JP6218084B2 (ja) 2012-10-04 2017-10-25 国立研究開発法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015012205A1 (ja) 2013-07-23 2015-01-29 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
KR20180123021A (ko) 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 신질환의 치료를 위한 의약
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
CA2075621A1 (en) 1990-02-13 1991-08-14 William J. Greenlee Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
US5140037A (en) 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
EP0503785B1 (en) 2001-04-25
FI955248A0 (fi) 1995-11-02
DE69231798T3 (de) 2012-07-12
HU211934A9 (en) 1996-01-29
IL101034A0 (en) 1992-11-15
FI955248A7 (fi) 1995-11-02
CN1101384C (zh) 2003-02-12
CZ51692A3 (en) 1993-03-17
HK1011361A1 (en) 1999-07-09
DE69231801T2 (de) 2001-12-06
NL300375I1 (nl) 2009-04-01
LU91330I2 (fr) 2007-06-04
JPH07121918B2 (ja) 1995-12-25
LU91571I2 (fr) 2009-07-13
FI112942B (fi) 2004-02-13
ES2157895T3 (es) 2001-09-01
NO954507L (no) 1992-08-24
FI920749A0 (fi) 1992-02-20
IS1756B (is) 2000-12-28
NO920688L (no) 1992-08-24
CA2061607C (en) 1999-01-19
NL300133I1 (nl) 2003-10-01
NO304516B1 (no) 1999-01-04
EP0503785A1 (en) 1992-09-16
DK0545912T3 (da) 2001-06-18
CA2229000A1 (en) 1992-08-22
KR920016429A (ko) 1992-09-24
ES2157895T7 (es) 2012-06-14
IL114996A0 (en) 1995-12-08
DE122011000011I1 (de) 2011-06-16
FI920749A7 (fi) 1992-08-22
DE10299043I2 (de) 2003-08-07
EP0503785B3 (en) 2012-02-29
PT545912E (pt) 2001-08-30
NO2011013I1 (no) 2011-08-22
CN1065063A (zh) 1992-10-07
ATE200778T1 (de) 2001-05-15
DE69231798T2 (de) 2001-12-06
IE970752A1 (en) 2000-02-23
RU95101430A (ru) 1997-02-20
IL101034A (en) 1996-10-16
HU9200578D0 (en) 1992-05-28
IS3819A (is) 1992-08-22
FI112941B (fi) 2004-02-13
HU9601179D0 (en) 1996-07-29
NO954507D0 (no) 1995-11-09
DK0503785T3 (da) 2001-06-18
FI112942B3 (fi) 2012-03-13
CA2229000C (en) 2002-04-09
CN1121859C (zh) 2003-09-24
ATE200777T1 (de) 2001-05-15
KR0128289B1 (ko) 1998-04-02
NL300227I1 (nl) 2006-06-01
EP0545912A2 (en) 1993-06-09
CN1189490A (zh) 1998-08-05
CA2061607A1 (en) 1992-08-22
AU647887B2 (en) 1994-03-31
DE10299043I1 (de) 2003-03-27
AU1112592A (en) 1992-08-27
IL114996A (en) 1997-07-13
JPH0578328A (ja) 1993-03-30
HUT60475A (en) 1992-09-28
HU223667B1 (hu) 2004-11-29
DE122005000051I1 (de) 2006-01-26
NO2006012I1 (no) 2006-10-30
EP0545912A3 (en) 1993-06-16
IE920540A1 (en) 1992-08-26
GR3035909T3 (en) 2001-08-31
CN1188645A (zh) 1998-07-29
DE122009000024I1 (de) 2009-09-17
CN1045770C (zh) 1999-10-20
NO920688D0 (no) 1992-02-21
NO2003009I2 (en) 2007-12-11
RU2128173C1 (ru) 1999-03-27
LU91056I2 (fr) 2004-10-19
PT503785E (pt) 2001-08-30
GR3035906T3 (en) 2001-08-31
NO2009019I1 (no) 2009-09-21
NL300133I2 (nl) 2004-03-01
LU91847I2 (fr) 2011-09-26
NO304516B3 (no) 2012-06-11
CZ289194B6 (cs) 2001-11-14
HU223338B1 (hu) 2004-06-28
EP0545912B1 (en) 2001-04-25
NZ241681A (en) 1993-07-27
DE69231801D1 (de) 2001-05-31
DE69231798D1 (de) 2001-05-31
HK1011969A1 (en) 1999-07-23
NO304517B1 (no) 1999-01-04

Similar Documents

Publication Publication Date Title
ES2156866T3 (es) Derivados de 1-bifenilmetilimidazol, su preparacion y su uso terapeutico.
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
DE3855575D1 (de) Wasserlösliche Camptothecin-Analoge
ATE94065T1 (de) Diazepine enthaltende pharmazeutische zusammensetzungen mit plaettchen aktivierender faktor (paf)-antagonistischer wirkung.
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
KR870007205A (ko) 펩티딜아미노디올
KR910006241A (ko) 피리미딘-4,6-디카복실산 디아미드, 이의 제조방법, 이의 용도 및 이들 화합물을 기초로 하는 약제
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
AR241422A1 (es) Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas.
IL70477A (en) Dihydropyridines and pharmaceutical compositions containing them
MX9307946A (es) Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso.
ES534505A0 (es) Un procedimiento para la preparacion de compuestos de 1, 4-dihidropiridina
MX9205792A (es) Derivados novedosos de asa-androstan 178-substituidos
ES2000456A6 (es) Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas.
BR9911145A (pt) Composto, uso de um composto, composição farmacêutica, e, processo para tratamento de um mamìfero e para a preparação de compostos
AR023111A1 (es) Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden
MX9203233A (es) Compuestos amino heterociclicos y composicion farmaceutica que los contiene.
KR890012990A (ko) 삼치환된 아민 이들의 제법 및 이들을 함유하는 제약조성물
ES388759A1 (es) Procedimiento para la obtencion de 3,4-dihidro-quinazolino-nas.
MX9304403A (es) Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol
BR9809473A (pt) Mistura fungida, e, processo para controlar fungos nocivos
ES343818A1 (es) Procedimiento para la obtencion de nuevas 3-amino - sidno- minas sustituidas.
ES2052783T3 (es) Procedimiento para la preparacion de 4-alquil-1,4-dihidropiridinas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 545912

Country of ref document: ES